Sonoma Pharmaceuticals Inc. reported its financial results for the quarter ended December 31, 2025. The company highlighted a 31 percent increase in revenues from Europe, attributed to higher demand for its products. Revenues in Asia grew 38 percent, while the Rest of World region saw a 50 percent rise, driven by customers placing larger, less frequent orders to benefit from quantity discounts and reduced shipping costs. In contrast, Latin America revenues decreased by 26 percent, primarily due to the timing of customer orders for overflow manufacturing. Sonoma Pharmaceuticals continues to focus on expanding sales of over-the-counter products and increasing sales through new and existing distributors. The company also sells hard surface disinfectant products through its partner MicroSafe into Europe, the Middle East, and Australia. The aerosol disinfectant solution has been positioned for use in areas susceptible to the spread of infectious diseases, which could contribute to epidemic or pandemic prevention efforts. The company remains dependent on third-party distributors and is monitoring regulatory developments and market conditions in its core regions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sonoma Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-000889), on February 10, 2026, and is solely responsible for the information contained therein.